Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3
- 31 July 2007
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 34 (5) , 493-502
- https://doi.org/10.1016/j.nucmedbio.2007.03.006
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphomaSeminars in Oncology, 2005
- Development of 131I-tositumomabSeminars in Oncology, 2005
- 99mTc Anti-CD 15 Monoclonal Antibody (LeuTech) Imaging Improves Diagnostic Accuracy and Clinical Management in Patients With Equivocal Presentation of AppendicitisAnnals of Surgery, 2002
- Radiometal-Labeled Agents (Non-Technetium) for Diagnostic ImagingChemical Reviews, 1999
- Therapeutic RadiopharmaceuticalsChemical Reviews, 1999
- 99mTc-Labeled Small Peptides as Diagnostic RadiopharmaceuticalsChemical Reviews, 1999
- Capromab PendetideDrugs & Aging, 1998
- lndium-111 Oncoscint CR/OV and F-18 FDG in Colorectal and Ovarian Carcinoma Recurrences Early ObservationsClinical Nuclear Medicine, 1995
- A Facile, Water-Soluble Method for Modification of Proteins with DOTA. Use of Elevated Temperature and Optimized pH To Achieve High Specific Activity and High Chelate Stability in Radiolabeled ImmunoconjugatesBioconjugate Chemistry, 1994
- Chelating agents for the binding of metal ions to macromoleculesNature, 1974